‘Potent’ antibiotic drug boosts fight against superbugs


New molecule proves effective in animals against several drug-resistant bacteria. 6park.com
新分子在动物体内证明能有效对抗多种耐药细菌。



Scientists have invented a potential drug candidate that successfully combats antibiotic-resistant “superbugs” in non-human tests, according to research. 6park.com
根据研究，科学家发明了一种潜在的药物候选，成功地在非人类测试中对抗抗生素耐药的“超级细菌”。 6park.com
     6park.com
The new antibiotic, known as cresomycin, is effective in mice against several bacteria that cause serious infections and are increasingly resistant to existing treatments, said a paper published in Science on Thursday. 6park.com
科学周四发表的一篇论文称，新型抗生素克克雷索霉素(cresomycin)对多种引起严重感染且对现有治疗方法越来越耐药的细菌在小鼠身上具有疗效。 6park.com
     6park.com
“What is most important is that it kills antibiotic-resistant strains in animals,” said Yury Polikanov, co-author of the research and an associate professor of biological sciences at the University of Illinois Chicago. “It’s more potent [than its predecessors] — and more potent against deadly bacteria.” 6park.com
“最重要的是它能够杀死动物体内的抗生素耐药菌株，”研究的合着者、伊利诺伊大学芝加哥分校的生物科学副教授尤里•波利卡诺夫(Yury Polikanov)说。“它比之前的更强大，对致命细菌的杀伤力更强。” 6park.com
      6park.com
Cresomycin’s synthesis is part of urgent research efforts to defeat anti-microbial resistance (AMR), which occurs when bacteria, viruses, fungi and parasites evolve the ability to resist treatments. 6park.com
克雷索霉素的合成是为了应对抗微生物耐药性(AMR)而进行的紧急研究之一，当细菌、病毒、真菌和寄生虫进化出抵抗治疗的能力时，就会出现抗微生物耐药性。 6park.com
     6park.com
AMR, largely caused by excessive use of antibiotics, is already linked to 5mn deaths a year, according to the World Health Organization. Hospitals are particularly susceptible to the spread of superbugs. 6park.com
根据世界卫生组织(World Health Organization)的说法，由于过度使用抗生素，抗微生物耐药性已经与每年500万人的死亡有关。医院特别容易传播超级细菌。 6park.com
     6park.com
Cresomycin proved effective against a range of dangerous bacteria prominent in the spread of AMR, the paper said. These include: Staphylococcus aureus, which causes infections in the skin and other organs; Escherichia coli (E-coli), responsible for intestinal and urinary tract illnesses; and Pseudomonas aeruginosa, a trigger of blood and lung infections. 6park.com
据该论文称，克雷索霉素对抗微生物耐药性传播中的一系列危险细菌表现出了良好的效果。这些细菌包括：金黄色葡萄球菌，它引起皮肤和其他器官的感染；大肠杆菌，它导致肠道和尿路疾病；以及铜绿假单胞菌，它是引发血液和肺部感染的触发因素。 6park.com
     6park.com
A big obstacle to dealing with AMR is that decades of under-investment in research has led to a lack of promising new synthetic antibiotics. Healthcare has long benefited from treatments derived from natural products, such as penicillins and cephalosporins obtained from moulds, but these are becoming increasingly ineffective as pathogens evolve to beat them. 6park.com
应对抗微生物耐药性的一个重大障碍是几十年来在研究方面的投资不足，导致缺乏有前途的新型合成抗生素。长期以来，医疗保健一直受益于源自天然产物的治疗方法，例如从霉菌中获得的青霉素和头孢菌素，但随着病原体进化以击败它们，这些方法变得越来越无效。 6park.com
     6park.com
The cresomycin paper’s authors acknowledged that the antibiotic problem was “daunting” but said their findings boosted hopes for “the future discovery of antibacterial agents broadly effective against AMR”. 6park.com
克雷索霉素论文的作者承认抗生素问题“令人望而生畏”，但表示他们的研究结果增加了对“未来发现广泛有效的抗微生物耐药性”的希望。 6park.com
     6park.com
The researchers took an existing antibiotic as cresomycin’s inspiration but then remodelled it and added extra features to deal with the changes AMR had caused in the target pathogens, Polikanov said. 6park.com
波利卡诺夫说，研究人员以现有的抗生素作为克雷索霉素的灵感，然后对其进行改造，并添加了额外的特性来应对抗微生物耐药性对目标病原体造成的变化。 6park.com
     6park.com
The cresomycin test results looked “promising”, said Tim Walsh, an Oxford university professor and AMR expert. More data would be needed on the molecule’s effectiveness against the group of so-called Gram-negative bacteria, which are protected by an outer membrane and are a central problem in the spread of AMR, Walsh added. 6park.com
牛津大学教授、抗微生物耐药性专家蒂姆•沃尔什(Tim Walsh)表示，克雷索霉素的测试结果“令人鼓舞”。沃尔什补充说，还需要更多关于该分子对所谓的革兰阴性细菌的有效性的数据，这些细菌受到外膜的保护，在抗微生物耐药性传播中是一个核心问题。 6park.com
     6park.com
“Until it is further scrutinised, it is difficult to predict the value of this new antibiotic against serious Gram-negative infections as a singular therapeutic,” said Walsh, who was not involved in the study. “But the elegant synthetic design of cresomycin, based on an intuitive rationale, provides an exciting scaffold for further development.” 6park.com
沃尔什没有参与这项研究，他说：“在进一步研究之前，很难预测这种新抗生素作为一种单一疗法对严重革兰氏阴性菌感染的价值。但基于直观的原理，克雷索霉素优雅的合成设计为进一步开发提供了令人兴奋的支架。” 6park.com
     6park.com
Swiss pharmaceutical company Roche is conducting phase 1 clinical trials on an antibiotic that successfully targeted a Gram-negative bacterium known as carbapenem-resistant Acinetobacter baumannii, or Crab. Scientists said the candidate drug’s discovery, unveiled in a paper last month, could be the basis for research on whether it could be reformulated to target other antibiotic-resistant pathogens.   6park.com
瑞士罗氏制药公司正在进行一种抗生素的一期临床试验，该抗生素成功针对了一种革兰氏阴性细菌，即耐碳青霉烯的鲍曼不动杆菌(Crab)。科学家们表示，上个月在一篇论文中公布的候选药物的发现可能是研究其是否可以重新配方以靶向其他抗生素耐药性病原体的基础。 6park.com
     6park.com
Crab, which causes life-threatening illnesses in hospital patients, is classed as a priority concern by the WHO and an urgent threat by the US Centers for Disease Control and Prevention. 6park.com
鲍曼不动杆菌被世界卫生组织(WHO)列为优先关注的问题，并被美国疾病控制与预防中心(Centers for Disease Control and Prevention)视为紧急威胁，该疾病会对医院患者的生命构成威胁。